The verdict
Our read at a glance.
Whether lanreotide's approved endocrine and neuroendocrine-tumor uses are understood within those specific indications, rather than generalized.
- The signal
- Randomized evidence, including the CLARINET trial, supports lanreotide for slowing progression of gastroenteropancreatic neuroendocrine tumors. It also lowers growth hormone and IGF-1 in acromegaly and controls carcinoid symptoms.
- The unknown
- Its comparative positioning against octreotide and newer agents, and long-term outcomes and tolerability across tumor types.
- Our read
- A proven, specialized hormone-suppressing drug with real anti-tumor evidence in neuroendocrine tumors, not a general wellness peptide. The point is to keep it to its approved endocrine and oncology indications and respect its metabolic and gallbladder effects.
The mechanism
How it works.
Lanreotide is a synthetic eight-amino-acid somatostatin analog, formulated as a long-acting depot that releases slowly after deep injection. It binds somatostatin receptors (mainly the SSTR2 subtype) on secretory and tumor cells and switches their output off, lowering growth hormone and IGF-1 in acromegaly and reducing the hormone-driven flushing and diarrhea of carcinoid syndrome. In gastroenteropancreatic neuroendocrine tumors the same receptor signaling also slows cell proliferation, which is the basis for its antitumor effect shown in the CLARINET trial.
Safety & regulatory boundary
The consequential part.
Lanreotide can cause gallbladder problems such as gallstones, changes in blood glucose, and other effects, and it is approved for specific endocrine and neuroendocrine indications. Somatuline Depot is the approved long-acting product and is not the same as compounded or research-labeled lanreotide, and the approved uses do not extend to general wellness or weight claims.
What's next
What we're watching.
Long-term neuroendocrine tumor outcomes, comparative data with octreotide, and combination strategies in oncology.
Context
Why this is discussed.
Lanreotide is a long-acting option for acromegaly and neuroendocrine tumors, and it is frequently compared with octreotide.
The evidence base
23 cited references.
Regulatory & labels3
Cipla USA Inc. (FDA label) · 2024
Cipla USA Inc. (FDA label) · 2025
Ipsen Biopharmaceuticals, Inc. (FDA label) · 2024
Registered trials8
ClinicalTrials.gov · PHASE3 · RECRUITING · 2025-11-19
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2026-03-06
ClinicalTrials.gov · PHASE1/PHASE2 · RECRUITING · 2021-09-17
ClinicalTrials.gov · PHASE3 · COMPLETED · 2014-09-19
ClinicalTrials.gov · PHASE3 · RECRUITING · 2025-05-09
ClinicalTrials.gov · PHASE3 · RECRUITING · 2022-03-24
ClinicalTrials.gov · PHASE2 · COMPLETED · 2022-04-22
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2019-06-17
Indexed literature (PubMed)12
Colao A et al. · Nat Rev Dis Primers · 2019
Feingold KR et al. · 2000
Caplin ME et al. · N Engl J Med · 2014
Goltstein LCMJ et al. · Lancet Gastroenterol Hepatol · 2021
Feingold KR et al. · 2000
Gomes-Porras M et al. · Int J Mol Sci · 2020
PubMed · 2012
Zhang B et al. · Endocr Rev · 2025
Tilak M et al. · Indian J Cancer · 2023
Gadelha MR et al. · J Clin Endocrinol Metab · 2024
Ito T et al. · Expert Opin Pharmacother · 2016
PubMed · 2006
Keep reading